Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide

Abstract

Thirteen patients with active acromegaly despite previous surgery were treated with 30 mg lanreotide im twice a month for 9 months. In 10 subjects the treatment continued to 19 months. GH serum levels of all patients decreased significantly from an initial value of 32.0 (29.4) micrograms/l [median (standard error of median)] to 10.0 (3.6) and 19.1 (5.7) after 3 and 9 months of treatment, respectively. In the 10 patients with the treatment longer than one year the decrease in GH was from 46.8 (29.4) micrograms/l to 12.5 (5.0) and 16.1 (5.3) after 13 and 19 months, respectively. IGF-I serum levels decreased significantly from 1193 (73) micrograms/l to 782 (99) and 621 (103) after 3 and 9 months, respectively, and were normalized in 3 patients. In the 10 patients treated for longer than one year, levels decreased significantly from 1318 (74) micrograms/l to 653 (170) and 742 (180) after 13 and 19 months, respectively. IGF BP-3 levels were reduced to the normal range in 6 patients and decreased from 8.7 (1.5) mg/l to 6.4 (0.8) and to 5.4 (1.0) after 3 and 9 months, respectively. In the patients with the 19 months treatment the decrease was from 9.3 (1.6 mg/l to 3.9 (0.9) and 4.8 (0.9) after 13 and 19 months, respectively. The IGF BP-3 to IFG I ratio increased in 7 patients. This elevation significantly correlated with the decrease in bioassayable somatomedin. Prolactin serum levels fell in all patients with increased prolactin secretion.(ABSTRACT TRUNCATED AT 250 WORDS)

Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR

“…Since the baseline IGF-I status did not influence the outcome of mean GH levels, we suggest that L-Autogel treatment can control clinical symptoms of acromegaly irrespective of GH levels. This has indeed been previously reported for lanreotide SR (8,35) and for octreotide LAR (23,24). Interpretation of our data is, however, limited by the nature of our open, one-way protocol.…”

An Open, Phase III Study of Lanreotide(Somatuline PR) in the Treatment of Acromegaly.

“…Further study will be required to prove this. Our study on the responses of GH and IGF-I after lanreotide treatment is similar to the results of AJ-Maskari et al [15] and Marek et al [20]. These finding of a weaker response of IGF-I than GH after treatment are similar to the results after octreotide treatment [27,28].…”

“…Long-term effects of lanreotide confirmed the efficacy and the tolerance of 30 mg intramuscularly every 10-14 days to control acromegaly [19,20].…”

Somatostatin agonists for treatment of acromegaly

“…a Frequencies are adopted from: octreotide LAR: http://www.rxlist.com according to manufacturer reports Cozzi et al, 2003;Davies et al, 1998;Flogstad et al, 1997;Jallad et al, 2005;Lancranjan and Atkinson, 1999;Lancranjan et al, 1996;Stewart et al, 1995); lanreotide autogel: Caron et al, 2002Caron et al, , 2006Lucas and Astorga, 2006); lanreotide SR: Attanasio et al, 2003;Caron et al, 1997;Chanson et al, 2000a,b;Giusti et al, 1996;Gutt et al, 2005;Lucas et al, 2003;Marek et al, 1994;Morange et al, 1994;Verhelst et al, 2000).…”